Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was under the impression that the only shares that were canceled were those of holders could not be reached, but I could be off and my bad if so. We should get clarity in the 2024 Q1 filing.
What is surprising is the total lack of interest at this point. Maybe once they start producing revenues/profit, this will get noticed.
In the old OTC days, these kinds of developments would have at least produced some volume and interest.
Interesting that Sam Dewar still owns 35.5 million shares. He is the original founder/owner of NHYf with a pretty impressive resume himself.
I wonder if he'll have any role moving forward or will he sell all when the price is right?
https://www.linkedin.com/in/sam-dewar-6ab115a
The last piece of housecleaning is now complete. Now we sit here at the starting line and watch the story unfold.
PR soon and expect a name and symbol change will come shortly.
Nice. Financials and PR next.
I like this part from the official PR
Mr. Randy Rivera, Director of Global Corporate Finance, said:
"The investment in NHYF is a logical step in GCF's strategy to invest in companies at the forefront of AI-powered medical technology. Companies with unique strategic investments in the AI medtech space have the potential to develop significant value over the next two to five years and we look forward to a long and productive association with NHYF".
Nice post. Global Corporate Finance, LLC is the investor you mention. Here is the official PR (for anyone new here).
Natural Harmony Foods Inc. Signs US$5,000,000 Equity Facility to Fund GrowthPress Release | 11/16/2023
NEW YORK, NY / ACCESSWIRE / November 16, 2023 / Publicly-held Natural Harmony Foods, Inc. (OTC PINK:NHYF) ("the Company") is pleased to announce today that it has entered into a Securities Purchase and Subscription Agreement with Global Corporate Finance Inc. ("GCF"), an esteemed private family office located in New York City, to provide working capital that will underpin the Company's growth.
?
The Securities Purchase and Subscription Agreement will enable the Company to draw up to US$5,000,000 at its discretion over a period of 30 months. In return for each drawdown, the Company will issue common stock at discount of 9% to the Company's average daily volume weighted stock price during the five (5) consecutive trading days immediately preceding the date of the Company's drawdown request. The cost of securing the facility is considered to be appropriate for the transaction.
The funds will be used to launch the first of the Company's nutraceutical products; the acquisition and development (subject to due diligence) of AI-based intellectual property; and general working capital, including up-listing the Company to OTCQB status as quickly as possible.
Mr. Randy Rivera, Director of Global Corporate Finance, said:
"The investment in NHYF is a logical step in GCF's strategy to invest in companies at the forefront of AI-powered medical technology. Companies with unique strategic investments in the AI medtech space have the potential to develop significant value over the next two to five years and we look forward to a long and productive association with NHYF".
Mr. Claudio Solitario, CEO of Natural Harmony Foods Inc. adds:
"We are delighted to be partnering with Global Corporate Finance Inc. and are very grateful for their financial support. The facility will provide the capital required to execute our growth plans and build shareholder value. Our collaboration with GCF is a testament to our shared vision for innovation and growth. The capital will serve as a dynamic catalyst to propel our strategic initiatives forward. We too look forward to a long and productive working relationship with GCF".
For media and Investor Relations inquiries, please contact: ir@nhyf.net
Thanks for the clarification on the filing dates, etc. Hopefully good times ahead for all those who have been patient with this one.
No worries here, we didn't come all this way to not file a 2023 report before we even get started.
I was just letting him know I'd expect to see something filed and possibly a PR by 4/14, which is a Sunday, so maybe by Friday the 12th.
A notice of late filing was posted yesterday.
https://www.otcmarkets.com/stock/NHYF/disclosure
This filing gives them until 4/14/24 to file the 2023 annual report. I bet we get a PR to go along with it.
Nice PR, straight facts, no fluff, no BS. I like it, but most P&D chasers won't.
This part caught my eye..
"I am pleased to announce the successful conclusion of my role as custodian of NHYF. I have instructed my attorney to formally discharge the custodianship."
If my assumption is correct, there can be no R/S for one year from this date since the custodianship is now concluded, effective 3/26/24. No R/S can occur before 3/26/25 per terms of the original agreement.
Any legal minds in this that can confirm or deny?
Agree...PR out today re: share cancelation
Reposting from September..
Yesterday's PR mentioned a partnership with a Dr. Robert Lawrence. I'm not 100% sure if this is him but if it is, he's got an impressive resume. This team is going to be the real deal.
https://www.egh1.com/resdev.html
Research & Development
In 1991, Dr. Robert Lawrence, PhD. Biomedical Engineering, PhD. Nuclear Physics, MS Microbiology, MS Computer Science and world-renowned Polymer Physicist, developed an oral delivery system for Growth Hormone (GH). Dr. Lawrence was later named Chief Science Officer of the $2.8 million dollar project initiated by Bushard Pharmaceuticals. He developed a unique vegetable-based enzyme polymer, which allowed large molecule such as Growth Hormone to be absorbed via the oral mucosa. Between 1991 and 1997, thousands of scientific studies were conducted in five major U.S. cities by Bushard's medical team under the thorough supervision of Dr. Lawrence. These studies verified the validity of this new and revolutionary oral application of GH.
Tested were people between the ages of 31 and 89 with average to fair health conditions. Protocols for the studies included: fasting from all nutritional vitamins and supplements two weeks prior to study, IRB Study Protocols, IGF-1 (insulin-like growth factor, type 1), HDL and LDL levels prior to and during all testing and S.M.A.C. test (liver enzymes and kidney enzymes). Levels of the above tests were conducted every 30 days to determine the efficacy of the new oral spray application.
The results were astounding -- not only were there no side effects, but test subjects had an average increase in their IGF-1 levels of 30% every 30 days. In 90 days, most of the test subjects had doubled their IGF-1 levels, which represented a measurable improvement in biological age as effective -- or in some cases, more effective -- as had been found with patients taking injections of Growth Hormone! Cholesterol levels were diminished in over 80% of patients by an average of 14.8%, and triglyceride levels also diminished by 31%. Noted were increases in mental stability, lean muscle mass, energy, libido, skin rejuvenation, and reacquired hair color and density. Also noted were reductions in excess weight, blood pressure and blood sugar.
When the project concluded in 1997, Bushard Pharmaceuticals, due to failed markets at the time, closed its doors permanently. In the following year, interested opportunists came out with oral spray Growth Hormone products, substandard to the original formulation. These manufacturers of oral GH used cheap plastic, petroleum-based polymers -- costing only a few dollars per gallon and of questionable health consequences. Dr. Lawrence was disappointed with the mockery that had been bestowed upon his discoveries and set out to recreate the original formulation he developed as a totally vegetarian, safe & effective polymer. The original polymer created by Dr. Lawrence had a purchase value of over $62,000 per gallon and was backed up by seven years of successful clinical studies. He began to produce the product for his family and friends, and shortly thereafter, he formulated Human Growth Hormone Replacement Therapy GH1 Oral Spray Growth Hormone.
EGH-1 has been tested extensively with many methods and modalities of today's modern science, most notably the VEGA Machine from Germany, which is a very refined form of electro-dermal, precision instrumentation used in medical practices today. The VEGA Machine measures a person's positive or negative reaction to a given substance. EGH-1 was recently featured as an exemplary product at the International VEGA Symposium in Grieshaber, Germany.
There are now over 25 documented health benefits associated with EGH-1. Testimonials from all over the world acknowledge a wide variety of physiological, emotional and mental improvements. Consistent use of EGH-1 stimulates a very natural process in the human system whereby one's own pituitary gland resumes secretion of Growth Hormone at levels which occurred during youth, thereby regulating the entire endocrine system, including modulation of hormones, blood pressure and cholesterol levels.
JB,
I'm reposting this press release from September as a reminder to all of their plan to develop and deliver in the AI Healthcare solutions space.
It's a good read, and if you look at some of the names they will be partnering with, there appears to be some serious brilliant minds coming together here.
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / Publicly-held Natural Harmony Foods, Inc. (OTC PINK:NHYF) (the Company) announces that following the change of control to Mr. Claudio Solitario, announced recently, the Company is now on a transformative path, signaling a compelling strategic direction. The Company's transition under Claudio's leadership signifies a dynamic shift towards innovation and growth, underpinned by his extensive knowledge and experience in medical technology and intellectual property development and commercialization.
?
Mr. Claudio Solitario
The Power of Artificial Intelligence Solutions in Healthcare
Central to NHYF's transformation is its commitment to harness the power of Artificial Intelligence (AI) in healthcare. AI-driven medical technology is set to revolutionize the field, promising faster, more accurate diagnoses; personalized treatment plans, and improved patient outcomes. AI's potential to transform the medical field is undeniable, offering promise of more efficient and effective healthcare for all. The Company will be at the forefront of this exciting advancement in medical technology focusing on the development of AI-powered screening methods and to this end, is forming strategic partnerships in an effort to co-develop the following:
Life-Saving Innovation: AI-based intellectual property for the fast and early identification of life threatening pulmonary embolisms using CAT scan detection software. A pulmonary embolism is a medical emergency; it may be fatal causing death. Pulmonary embolism affects around 900,000 people in the U.S. every year1. The AI-powered technology aims to improve the radiologic processing time and reading performance during emergency evaluations.
Facial Analysis to objectively screen for PTSD: AI-based facial analysis technology to objectively screen for post-traumatic stress disorder. The technology will analyze and interpret facial data, the result of which will be seen immediately by the user - with an option of sending it to their medical practitioner. This innovative approach will empower individuals and their healthcare providers to proactively manage mental health. The incidence of mental illness in the USA is well known; and the cost is estimated at $300Billion annually2. A quick and objective assessment of PTSD is required by patients and healthcare professionals alike.
Evolution in Evaluation and Treatment of Pain Management: A breakthrough new AI program (Chatbot) to simulate conversation with individuals suffering from chronic pain. The program will be designed to immediately address the pain sufferer's acute and chronic pain and provide viable options to consider as they search for a medical personnel who has the appropriate expertise. It will also create a written dialogue that can be reviewed by medical practitioners and may become an integral part of the pain sufferer's comprehensive pain management plan. This breakthrough AI-based technology, under the guidance of Dr. Robert Lawrence, a retired Neurologist with PhDs in Nuclear Physics and Biomedical Engineering, along with MS Degrees in Computer Science and Pharmacology, will be a game-changer for the over 51 million Americans (over 20% of the adult population3) affected by chronic pain.
AI's capacity to process vast volumes of data positions it as a pivotal tool in the aid to diagnosis across diverse medical domains. By leveraging machine learning algorithms, AI can analyze vast amounts of medical data, from patient records to medical images and by identifying patterns and insights that may escape human detection. This capability can lead to earlier and more accurate diagnoses, personalized treatment plans and improved patient outcomes. Importantly, AI-powered technologies can also enhance patient engagement, provide 24/7 support and help individuals manage their health proactively.
Innovative Nutritional Wellness Solutions for Early Revenue Opportunity
NHYF's vision extends beyond AI, encompassing innovative nutraceutical solutions. The company is poised to launch an anti-anxiety product - the first of its nutritional supplements that can be added to medical protocols for the long-term management of anxiety. The formula was scientifically designed as an active dietary supplement to nutritionally support the body's inherent abilities to positively respond to stressful conditions. It will address the needs of the great many people who are searching for natural supplements that may help address symptoms associated with their anxiety. David Anderson MD, a highly respected U.S. medical school-associated research physician will ensure all claims and presentations are maximized whilst complying with Regulatory Agency Guidelines.
The market for nutraceuticals in the USA has been experiencing robust growth, driven by increasing consumer awareness of the link between diet, health, and wellness. With a growing emphasis on preventive healthcare, the demand for dietary supplements and functional foods that offer potential health benefits beyond basic nutrition continues to expand, creating a dynamic landscape for the Company's nutraceutical businesses to flourish.
Change of OTC Market Company Status
The transition of the Company's business to the development of medical technology and the commercialization of wellness products will require a higher level of corporate governance and transparency. To this end the Company is working towards a change of status from Pink to OTCQB.
Speaking on behalf of the Company, newly appointed CEO, Mr. Claudio Solitario said: " We are excited to embark on this transformative journey. AI is fast becoming an important tool in the quest for faster and more accurate diagnoses. Our mission is to leverage AI to enhance health outcomes and reduce healthcare costs. We also look forward to launching our pioneering anti-anxiety formula, the first of our nutraceutical products. The market demand for nutraceuticals is significant and growing, representing an early revenue opportunity for the Company. The path ahead is exciting and we look forward to keeping shareholders abreast of progress in the coming weeks and months".
1 https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism
2 https://www.nami.org/Press-Media/In-The-News/2021/2020-devastated-US-mental-health-%E2%80%94-healing-must-be-a-priority
3 https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm#contribAff
For media and Investor Relations inquiries, please contact: ir@nhyf.net
The official website at www.nhyf.net
Updated share structure updated on OTC markets. I think we see a PR today or early next week to address to the cancelation and formal change of control.
NHYF SECURITY DETAILS
Share Structure
Market Cap ?
1,547,483
03/21/2024
Authorized Shares
600,000,000
03/21/2024
Outstanding Shares
309,496,511
03/21/2024
Restricted
33,240,000
03/21/2024
Unrestricted
276,256,511
03/21/2024
Held at DTC
273,334,274
03/21/2024
Float
276,256,511
06/15/2023
Par Value
0.001
Thanks for reposting this, I was thinking the same.
Here is another tweet that any potential new investors should be aware of.
$NHYF I have agreed to stay on as a consultant if needed or just be a resource as need arises. Synergy is keeping 1 Pref B share which is why I provided a lower price. I have a vested interest in the company successhttps://t.co/DDfOSnirL7
— Synergy Management (@synergymgtgroup) August 10, 2023
Excellent, thanks.
Philip O’Quigley, CEO of Falcon commented:
“The IP30 flow rate announced today of 3.2 MMcf/d, normalised to 6.4 MMcf/d over 1,000 metres, are truly stellar and mark a major turning point in the Beetaloo Basin. Not only did the results exceed Falcon’s pre-drill commercial threshold of a normalised flow rate of 3 MMcf/d by more than 100% but the geological properties evidenced in this part of the Basin, including reservoir pressure, effective porosity and gas-in-place all point towards the significant resource potential of the Basin. We will continue flow testing the well for the next 60 days to achieve an IP90 flow rate which will better determine what that resource potential is.
We can now look forward with confidence to commencing the proposed 40 MMcf/d pilot development project which will start with the drilling of the first of six 10,000 ft development wells in Q2 2024, subject to stakeholder approval and funding, and look forward to updating the market as those plans begin to materialise.”
The IP30 flow test extrapolates to ~19.5 MMcf/d for proposed future 10,000-foot (3,000 metres) development wells, in line with some of the highest flow rates achieved in the US Marcellus shale
Pretty good news today and a conference call at 11 am est.
https://falconoilandgas.com/2024/02/26/stellar-ip30-day-flow-rates-advances-the-beetaloo-to-pilot-development/
I won't speculate as to a pps. Every time I'm on one of these boards and I see someone say a double or triple 0 stock is going to 25 cents, 50 cents, or even a dollar, it just kills the legitimacy for me.
This company is in the AI, mental health and nutraceutical sectors, with a very impressive supporting cast, and Investor friendly financing.
I've followed hundreds of these penny tickers, and as far as these long shots go, this one has all the ingredients to pay off all of those who invested at the ground floor and remain patient a little longer.
All in my opinion.
I assume the company has to prove to the court that they attempted to reach all of the old shareholders of record.
I very much doubt that they were able to contact each and every one, but the attempt and non reply itself might be enough for the court to cancel. Hopefully.
Either way, I'm happy with the process to date. Even though it's taking a long time, I'd much rather see it being done correctly.
Just my opinion.
$NHYF the attempted service of all shareholders has been completed. The next step is the Motion for Cancellation of Shares and a hearing on it. More info to follow once I know timeframe on this.
— Synergy Management (@synergymgtgroup) February 19, 2024
Somebody(s) dumping on this tweet apparently. So it might take a little longer to reach old shareholders, if they ever do at all.
I'll be on the bid for some more.
$NHYF On further review it was determined that the case does not meet the criteria to effectuate service of process via publication. We will be effectuating service of process via Certified Mail R.R.R. on the five shareholders and filing an Affidavit of Diligent Search on same.
— Synergy Management (@synergymgtgroup) January 24, 2024
Honestly, I haven't done too much research or seen anything new lately. I'm more just wishing and hoping at this point.
500 shares traded today. Perhaps this baby can come back to life like so many other OTC tickers have done lately.
This is for the 100m share cancelation, which would benefit all of us, so let's hope they're successful.
I imagine a name/symbol change will come at some point a little further down the road.
$NHYF Update from attorney: We received all affidavits of service. We are currently working on the language for the notice by publication. Should have the fee for same and duration as soon as it is approved by the publisher.
— Synergy Management (@synergymgtgroup) January 9, 2024
There won't be any RS for at least one year per terms of the agreement.
$NHYF There are some additional stipulations I added that were agreed upon with this transaction. pic.twitter.com/QQraUiBzjy
— Synergy Management (@synergymgtgroup) August 9, 2023
For any possible new investors doing weekend DD and a reminder to current shareholders, here's what is on the horizon for NHYF.
https://www.bloomberg.com/press-releases/2023-09-19/natural-harmony-foods-inc-announces-new-strategic-direction-and-sets-the-stage-for-a-revolution-in-healthcare-and-wellness
Natural Harmony Foods Inc. Announces New Strategic Direction and Sets the Stage for a Revolution In Healthcare and Wellness
September 19, 2023 at 10:03 AM EDT
NEW YORK, NY / ACCESSWIRE / September 19, 2023 / Publicly-held Natural Harmony Foods, Inc. (OTC PINK:NHYF) (the Company) announces that following the change of control to Mr. Claudio Solitario, announced recently, the Company is now on a transformative path, signaling a compelling strategic direction. The Company's transition under Claudio's leadership signifies a dynamic shift towards innovation and growth, underpinned by his extensive knowledge and experience in medical technology and intellectual property development and commercialization. Mr. Claudio Solitario The Power of Artificial Intelligence Solutions in Healthcare Central to NHYF's transformation is its commitment to harness the power of Artificial Intelligence (AI) in healthcare. AI-driven medical technology is set to revolutionize the field, promising faster, more accurate diagnoses; personalized treatment plans, and improved patient outcomes. AI's potential to transform the medical field is undeniable, offering promise of more efficient and effective healthcare for all. The Company will be at the forefront of this exciting advancement in medical technology focusing on the development of AI-powered screening methods and to this end, is forming strategic partnerships in an effort to co-develop the following: * Life-Saving Innovation: AI-based intellectual property for the fast and early identification of life threatening pulmonary embolisms using CAT scan detection software. A pulmonary embolism is a medical emergency; it may be fatal causing death. Pulmonary embolism affects around 900,000 people in the U.S. every year^1. The AI-powered technology aims to improve the radiologic processing time and reading performance during emergency evaluations. * Facial Analysis to objectively screen for PTSD: AI-based facial analysis technology to objectively screen for post-traumatic stress disorder. The technology will analyze and interpret facial data, the result of which will be seen immediately by the user - with an option of sending it to their medical practitioner. This innovative approach will empower individuals and their healthcare providers to proactively manage mental health. The incidence of mental illness in the USA is well known; and the cost is estimated at $300Billion annually^2. A quick and objective assessment of PTSD is required by patients and healthcare professionals alike. * Evolution in Evaluation and Treatment of Pain Management: A breakthrough new AI program (Chatbot) to simulate conversation with individuals suffering from chronic pain. The program will be designed to immediately address the pain sufferer's acute and chronic pain and provide viable options to consider as they search for a medical personnel who has the appropriate expertise. It will also create a written dialogue that can be reviewed by medical practitioners and may become an integral part of the pain sufferer's comprehensive pain management plan. This breakthrough AI-based technology, under the guidance of Dr. Robert Lawrence, a retired Neurologist with PhDs in Nuclear Physics and Biomedical Engineering, along with MS Degrees in Computer Science and Pharmacology, will be a game-changer for the over 51 million Americans (over 20% of the adult population^3) affected by chronic pain. AI's capacity to process vast volumes of data positions it as a pivotal tool in the aid to diagnosis across diverse medical domains. By leveraging machine learning algorithms, AI can analyze vast amounts of medical data, from patient records to medical images and by identifying patterns and insights that may escape human detection. This capability can lead to earlier and more accurate diagnoses, personalized treatment plans and improved patient outcomes. Importantly, AI-powered technologies can also enhance patient engagement, provide 24/7 support and help individuals manage their health proactively. Innovative Nutritional Wellness Solutions for Early Revenue Opportunity NHYF's vision extends beyond AI, encompassing innovative nutraceutical solutions. The company is poised to launch an anti-anxiety product - the first of its nutritional supplements that can be added to medical protocols for the long-term management of anxiety. The formula was scientifically designed as an active dietary supplement to nutritionally support the body's inherent abilities to positively respond to stressful conditions. It will address the needs of the great many people who are searching for natural supplements that may help address symptoms associated with their anxiety. David Anderson MD, a highly respected U.S. medical school-associated research physician will ensure all claims and presentations are maximized whilst complying with Regulatory Agency Guidelines. The market for nutraceuticals in the USA has been experiencing robust growth, driven by increasing consumer awareness of the link between diet, health, and wellness. With a growing emphasis on preventive healthcare, the demand for dietary supplements and functional foods that offer potential health benefits beyond basic nutrition continues to expand, creating a dynamic landscape for the Company's nutraceutical businesses to flourish. Change of OTC Market Company Status The transition of the Company's business to the development of medical technology and the commercialization of wellness products will require a higher level of corporate governance and transparency. To this end the Company is working towards a change of status from Pink to OTCQB. Speaking on behalf of the Company, newly appointed CEO, Mr. Claudio Solitario said: " We are excited to embark on this transformative journey. AI is fast becoming an important tool in the quest for faster and more accurate diagnoses. Our mission is to leverage AI to enhance health outcomes and reduce healthcare costs. We also look forward to launching our pioneering anti-anxiety formula, the first of our nutraceutical products. The market demand for nutraceuticals is significant and growing, representing an early revenue opportunity for the Company. The path ahead is exciting and we look forward to keeping shareholders abreast of progress in the coming weeks and months". ^1 https://www.lung.org/lung-health-diseases/l ung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism ^2 https://www.nami.org/Press-Media/In-The-New s/2021/2020-devastated-US-mental-health-%E2%80%94-healing-must-be-a-priority ^3 https://www.cdc.gov/mmwr/volumes/72/wr/mm72 15a1.htm#contribAff For media and Investor Relations inquiries, please contact: ir@nhyf.net The official website at www.nhyf.net About Natural Harmony Foods Inc. Natural Harmony Foods Inc. (NHYF) aims to enhance patient outcomes and reduce healthcare costs by developing cutting-edge AI-powered methods to aid in the diagnosis of medical conditions. These methods enable early, accurate screening, contributing to quicker and more effective treatment. NHYF focuses on developing AI-based screening techniques for medical conditions, capitalizing on the growing role of AI in clinical practice. Additionally, NHYF acknowledges the thriving nutraceutical market's potential and plans to enter it for early revenue, benefiting from the growing emphasis on natural approaches and the demand for dietary supplements that offer potential health benefits beyond basic nutrition. The demand for nutraceuticals continues to expand, creating a dynamic landscape for NHYF's nutraceutical businesses to flourish. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements in this press include, among others, statements about our renegotiated settlement agreement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our limited operating history; our dependence on third parties for many aspects of our business; general market and economic conditions; technical factors; the availability of outside capital; our receipt of revenues; legislative developments; changes in our expenditures and other uses of cash; our ability to find, recruit and retain personnel in sufficient numbers to support our growth; our ability to manage growth; and general market, economic and business conditions. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. SOURCE: Natural Harmony Foods, Inc. via PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/785316/natural-harmony-foods-inc-announces-new-st rategic-direction-and-sets-the-stage-for-a-revolution-in-healthcare-and-wellness
I like what I'm seeing here. Alot.
The funds will be used to launch the first of the Company's nutraceutical products; the acquisition and development (subject to due diligence) of AI-based intellectual property; and general working capital, including up-listing the Company to OTCQB status as quickly as possible.
Mr. Randy Rivera, Director of Global Corporate Finance, said:
"The investment in NHYF is a logical step in GCF's strategy to invest in companies at the forefront of AI-powered medical technology. Companies with unique strategic investments in the AI medtech space have the potential to develop significant value over the next two to five years and we look forward to a long and productive association with NHYF".
Mr. Claudio Solitario, CEO of Natural Harmony Foods Inc. adds:
"We are delighted to be partnering with Global Corporate Finance Inc. and are very grateful for their financial support. The facility will provide the capital required to execute our growth plans and build shareholder value. Our collaboration with GCF is a testament to our shared vision for innovation and growth. The capital will serve as a dynamic catalyst to propel our strategic initiatives forward. We too look forward to a long and productive working relationship with GCF".
For media and Investor Relations inquiries, please contact: ir@nhyf.net
Titter: @NHYF_Official
The official website at www.nhyf.net
Per this tweet, 10-15 days from the 18th for a decision.
$NHYF
Court is on October 18th where I hope to have the judge order the parties whose shares are in question to be served. Response time is 10 - 15 days depending on service type. Apparently the judge's calendar is very full.
— Synergy Management (@synergymgtgroup) September 11, 2023
?
OTC Updates
🚨 $NHYF
💰0.0060
Pink Current, AS: 600M, OS: 386M, US: 276M
Business Description Updated:
🔴 Natural Harmony Foods Inc (NHYF) aims to enhance patient outcomes and reduce healthcare costs by developing cutting-edge AI-powered methods to aid in the diagnosis of medical conditions. These methods enable early, accurate screening, contributing to quicker and more effective treatment. NHYF focuses on developing AI-based screening techniques for medical conditions, capitalizing on the growing role of AI in clinical practice. Additionally, NHYF acknowledges the thriving nutraceutical market's potential and plans to enter it for early revenue, benefiting from the growing emphasis on natural approaches and the demand for dietary supplements that offer potential health benefits beyond basic nutrition. The demand for nutraceuticals continues to expand, creating a dynamic landscape for NHYF’s nutraceutical businesses to flourish.
🟢 Natural Harmony Foods Inc (NHYF) aims to enhance patient outcomes and reduce healthcare costs by developing cutting-edge AI-powered methods to aid in the diagnosis of medical conditions. These methods enable early, accurate screening, contributing to quicker and more effective treatment. NHYF focuses on developing AI-based screening techniques for medical conditions, capitalizing on the growing role of AI in clinical practice. Additionally, NHYF acknowledges the thriving nutraceutical market's potential and plans to enter it for early revenue, benefiting from the growing emphasis on natural approaches and the demand for dietary supplements that offer potential health benefits beyond basic nutrition. The demand for nutraceuticals continues to expand, creating a dynamic landscape for NHYF's nutraceutical businesses to flourish.
Chart, OTC Profile, Twitter, @otcupdates
242viewsOct 13 at 18:15
$NHYF
💰0.0049
Pink Current, AS: 600M, OS: 386M, US: 276M
Phone Updated:
🔴 +1 3124816850
🟢 +1 646 359 4854
Director(s) Added:
🟢Claude Solitario, Director
Director(s) Removed:
🔴Benjamin Robert Berry, Director
Officer(s) Added:
🟢Claude S
Yesterday's PR mentioned a partnership with a Dr. Robert Lawrence. I'm not 100% sure if this is him but if it is, he's got an impressive resume. This team is going to be the real deal.
https://www.egh1.com/resdev.html
Research & Development
In 1991, Dr. Robert Lawrence, PhD. Biomedical Engineering, PhD. Nuclear Physics, MS Microbiology, MS Computer Science and world-renowned Polymer Physicist, developed an oral delivery system for Growth Hormone (GH). Dr. Lawrence was later named Chief Science Officer of the $2.8 million dollar project initiated by Bushard Pharmaceuticals. He developed a unique vegetable-based enzyme polymer, which allowed large molecule such as Growth Hormone to be absorbed via the oral mucosa. Between 1991 and 1997, thousands of scientific studies were conducted in five major U.S. cities by Bushard's medical team under the thorough supervision of Dr. Lawrence. These studies verified the validity of this new and revolutionary oral application of GH.
Tested were people between the ages of 31 and 89 with average to fair health conditions. Protocols for the studies included: fasting from all nutritional vitamins and supplements two weeks prior to study, IRB Study Protocols, IGF-1 (insulin-like growth factor, type 1), HDL and LDL levels prior to and during all testing and S.M.A.C. test (liver enzymes and kidney enzymes). Levels of the above tests were conducted every 30 days to determine the efficacy of the new oral spray application.
The results were astounding -- not only were there no side effects, but test subjects had an average increase in their IGF-1 levels of 30% every 30 days. In 90 days, most of the test subjects had doubled their IGF-1 levels, which represented a measurable improvement in biological age as effective -- or in some cases, more effective -- as had been found with patients taking injections of Growth Hormone! Cholesterol levels were diminished in over 80% of patients by an average of 14.8%, and triglyceride levels also diminished by 31%. Noted were increases in mental stability, lean muscle mass, energy, libido, skin rejuvenation, and reacquired hair color and density. Also noted were reductions in excess weight, blood pressure and blood sugar.
When the project concluded in 1997, Bushard Pharmaceuticals, due to failed markets at the time, closed its doors permanently. In the following year, interested opportunists came out with oral spray Growth Hormone products, substandard to the original formulation. These manufacturers of oral GH used cheap plastic, petroleum-based polymers -- costing only a few dollars per gallon and of questionable health consequences. Dr. Lawrence was disappointed with the mockery that had been bestowed upon his discoveries and set out to recreate the original formulation he developed as a totally vegetarian, safe & effective polymer. The original polymer created by Dr. Lawrence had a purchase value of over $62,000 per gallon and was backed up by seven years of successful clinical studies. He began to produce the product for his family and friends, and shortly thereafter, he formulated Human Growth Hormone Replacement Therapy GH1 Oral Spray Growth Hormone.
EGH-1 has been tested extensively with many methods and modalities of today's modern science, most notably the VEGA Machine from Germany, which is a very refined form of electro-dermal, precision instrumentation used in medical practices today. The VEGA Machine measures a person's positive or negative reaction to a given substance. EGH-1 was recently featured as an exemplary product at the International VEGA Symposium in Grieshaber, Germany.
There are now over 25 documented health benefits associated with EGH-1. Testimonials from all over the world acknowledge a wide variety of physiological, emotional and mental improvements. Consistent use of EGH-1 stimulates a very natural process in the human system whereby one's own pituitary gland resumes secretion of Growth Hormone at levels which occurred during youth, thereby regulating the entire endocrine system, including modulation of hormones, blood pressure and cholesterol levels.
Since we are now in the business of nutraceuticals, a brief industry analysis..
https://www.google.com/amp/s/www.gminsights.com/industry-analysis/nutraceuticals-market/amp
Nutraceutical Industry Analysis
Nutraceutical Market size was worth more than USD 423 billion in 2022 and is poised to grow significantly at over 4.5% CAGR from 2023 to 2032 owing to the high prevalence of metabolic disorders worldwide.
Listed now on OTC markets
PRODUCTS AND SERVICES
AI-powered services to aid in the diagnosis of medical conditions. Nutraceuticals based in preventive healthcare.
Had to look up Neutraceutical , and I like what I'm seeing.
https://www.news-medical.net/health/Nutraceutical-Industry.aspx
Nutraceutical Industry
?By Dr. Tomislav Meštrovic, MD, Ph.D.Reviewed by Benedette Cuffari, M.Sc.
Nutraceuticals can be defined as any food product (or part thereof) which provides health benefits – including prevention and/or treatment of disease – in addition to the basic nutritional value found in foodstuff. Typically, nutraceutical products will be isolated from foods and subsequently sold in a medicinal form.
?
Image Credit: visivastudio / Shutterstock.com
The nutraceutical industry represents a dynamic and evolving entity that offers novel opportunities to merge scientific discovery with the growing consumer interest in health-enhancing foods. Nutraceuticals are of particular interest as a way to reduce the often expensive disease treatment approaches that are currently employed in developed countries.
The nutraceutical industry encompasses three main segments which include functional foods, dietary supplements, and herbal/natural products.
Global demand for nutraceuticals
Although the nutraceuticals industry first emerged in the early 1990s, the world witnessed its explosive growth during the first decade of this century. Between 1999 to 2002, the nutraceuticals industry grew at an annual average growth rate of 7.3 percent, whereas the growth rate of this industry over the past several years has doubled to 14.7 percent.
Today, the global nutraceutical market has an estimated worth of $117 billion USD. The development of more personalized and customizable products within the nutraceutical industry has gained increasing popularity, particularly in the more developed markets of the world. Some of the key strategies within the modern nutraceutical industry therefore involve increasing the investment in research and development projects to find innovative approaches, verifying health claims of the products and market research.
A primary impetus for the rapid growth of the nutraceutical industry is consumer demand. To this end, consumers are looking to follow healthy lifestyles and obtain optimum nutrition to keep diseases such as diabetes, high blood pressure and obesity at bay. Although the United States, European Union and India are currently the world's largest nutraceuticals markets, China is likely to surpass them all by 2030.
What Is A Nutraceutical? Pharmaceuticals Containing Bioactive Compounds Obtained From Food
The global nutraceutical industry
The United States nutraceutical market still represents the largest nutraceutical market in the world. In fact, many American companies are looking to diversify their products and move towards incorporating a greater number of natural ingredients in their products. This change of approach is largely a consequence of the push from American consumers, many of whom are extremely health-conscious and demand specific ingredients to be present in the products they consume.
?Food Adulteration in the Honey Industry eBook Learn how to test and ensure honey authenticity throughout the supply chain with this free eBook. Download the latest edition
The market for nutraceuticals in Europe is witnessing heavy consolidation, with a focus on innovation and new product development. By the year 2025, it is estimated that the compound annual growth rate of the European nutraceutical industry will reach 7.5%. Germany, Sweden and the Netherlands have emerged as the key nutraceutical innovation hubs of Europe, whereas Spain and Great Britain act as decisive test markets for new products.
According to a recent report, the total market for nutraceuticals in India is growing at a rate of 21% per year. It is currently a nascent market that is trying to incorporate traditional herbal ingredients, many of which are ayurvedic, into the nutraceutical portfolio. Still, its growth has surpassed global rates in recent years, mostly driven by functional food and beverages categories.
References
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645360/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336979/
http://www.thepharmajournal.com/vol1Issue11/Issue_jan_2013/4.1.pdf
Bagchi D. Nutraceutical and Functional Food Regulations in the United States and Around the World. Academic Press, 2008; pp. 1-36.
Further Reading
?
Written by
Dr. Tomislav Meštrovic
Dr. Tomislav Meštrovic is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community.
Researchers unravel structure of MCM8/9 enzyme linked to infertility and cancer
?
Is obesity associated with
$NHYF dealing with some minor logistics issues with the transfer agent. This is causing some delays but I am working through and hope to have them completed soon.
— Synergy Management (@synergymgtgroup) August 15, 2023
Wow, this is very interesting. Thanks